D. Boral Capital reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD - Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently have a $9.00 price objective on the stock.
Separately, HC Wainwright decreased their price target on Invivyd from $10.00 to $5.00 and set a "buy" rating on the stock in a research note on Wednesday, May 28th.
Read Our Latest Report on IVVD
Invivyd Price Performance
Shares of NASDAQ:IVVD traded down $0.07 during trading on Thursday, reaching $0.73. The company had a trading volume of 10,196,338 shares, compared to its average volume of 4,561,731. The firm has a market capitalization of $87.15 million, a price-to-earnings ratio of -0.61 and a beta of 0.63. The stock's fifty day moving average price is $0.76 and its 200 day moving average price is $0.76. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $2.74.
Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.10). Invivyd had a negative net margin of 389.01% and a negative return on equity of 165.24%. The company had revenue of $11.30 million during the quarter, compared to analyst estimates of $34.45 million. On average, equities analysts anticipate that Invivyd will post -1.64 EPS for the current fiscal year.
Institutional Trading of Invivyd
Several institutional investors and hedge funds have recently made changes to their positions in IVVD. Mithril II GP LP purchased a new stake in shares of Invivyd in the fourth quarter valued at $4,981,000. AQR Capital Management LLC lifted its position in shares of Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock valued at $249,000 after acquiring an additional 391,617 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Invivyd by 1,276.5% in the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock valued at $135,000 after acquiring an additional 282,100 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Invivyd by 35.2% in the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock valued at $385,000 after acquiring an additional 227,463 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Invivyd by 644.1% in the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock valued at $114,000 after acquiring an additional 222,375 shares in the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Read More
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
